B
Black Diamond Therapeutics, Inc. (BDTX)
NMS – Real vaqt narxi. Valyuta: USD
2.85
+0.02 (0.73%)
Bozor ochiq: May 13, 2026, 9:35 AM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
2.85
+0.02 (0.73%)
Bozor ochiq: May 13, 2026, 9:35 AM EDT
Black Diamond Therapeutics, Inc., klinik bosqichdagi onkologiya kompaniyasi, genetik jihatdan aniqlangan o'smalari bo'lgan bemorlar uchun MasterKey terapiyalarini kashf qilish va rivojlantirishga qaratilgan. Kompaniyaning asosiy dori nomzodi silevertinib bo'lib, u miyaga kiruvchi epidermal o'sish omili retseptorining MasterKey ingibitoridir. Bu dorining epidermal o'sish omili retseptorining mutatsiyaga uchragan mayda hujayrali o'pka saratonini davolash uchun 2-bosqichli klinik sinovi, shuningdek, glioblastomani davolash uchun 2-bosqichli klinik sinovi o'tkazilmoqda. Kompaniya, shuningdek, miyaga kiruvchi RAF MasterKey ingibitori bo'lgan BDTX-4933ni ishlab chiqmoqda. Bu dori qattiq o'smalarda KRAS, NRAS va BRAF o'zgarishlarini nishonga oladi va 1-bosqichli klinik sinovda. Bundan tashqari, kompaniya preklinik bosqichda bo'lgan BDTX-4876ni ishlab chiqmoqda. Bu dori FGFR1/4 ga nisbatan selektivlikka ega bo'lgan onkogenik FGFR2/3 mutatsiyalarining MasterKey ingibitoridir. Kompaniya avval ASET Therapeutics, Inc. nomi bilan tanilgan va 2018 yil yanvar oyida Black Diamond Therapeutics, Inc. nomini olgan. Black Diamond Therapeutics, Inc. 2014 yilda tashkil etilgan va Massachusets shtatining Kembrij shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Elizabeth Buck Ph.D. | Co-Founder & Chief Scientific Officer |
| Dr. Mark A. Velleca M.D., Ph.D. | CEO, President & Chairman |
| Dr. Sergey Yurasov M.D., Ph.D. | Chief Medical Officer |
| Mr. Brent Hatzis-Schoch Esq., J.D. | COO & General Counsel |
| Ms. Erika Jones | Principal Financial Officer, Principal Accounting Officer, SVP of Finance & Corporate Controller |
| Ms. Melanie Morrison |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-07 | 8-K | bdtx-20260507.htm |
| 2026-05-07 | 10-Q | bdtx-20260331.htm |
| 2026-04-29 | DEFA14A | tm261476d2_defa14a.htm |
| 2026-03-16 | S-8 | tm268810d1_s8.htm |
| 2026-03-16 | 8-K | bdtx-20260316.htm |
| 2026-03-16 | 10-K | bdtx-20251231.htm |
| 2025-12-03 | 8-K | tm2532577d1_8k.htm |
| 2025-12-01 | CORRESP | filename1.htm |
| 2025-11-13 | S-3 | tm2531084-1_s3.htm |
| 2025-11-06 | 10-Q | bdtx-20250930.htm |
| Chief Development Officer |